PolyTherics and TUBE Pharma Collaborate to Develop Novel Cytotoxic Payloads for Antibody Drug Conjugates
PolyTherics and TUBE Pharma Collaborate to Develop Novel Cytotoxic Payloads for Antibody Drug Conjugates (ADCs)
London, UK and Vienna, Austria, 15 October 2013 – PolyTherics Limited (“PolyTherics”) and TUBE Pharma GmbH (“TUBE”) announce that they are collaborating to produce reagents to link novel cytotoxic drugs developed by TUBE to antibodies using PolyTherics’ proprietary ThioBridge™ conjugation technology for the production of better antibody drug conjugates (ADCs).
TUBE has developed a series of proprietary synthetic tubulin-binding agents, referred to as cytolysins, which have been shown to be effective against a range of cancer cell lines, including drug-resistant cancer cells. Cytolysins rapidly trigger cell death and, conjugated to small molecules, polymers, proteins and peptides, they have shown significant efficacy in preclinical models of cancer.
PolyTherics has developed ThioBridge™, a site-specific conjugation technology, to attach cytotoxic payloads to whole antibodies, antibody fragments and other scaffolds. ThioBridge™ enables the production of ADCs with reduced heterogeneity and very good stability compared with alternative conjugation methods.
PolyTherics and TUBE can undertake feasibility studies for companies interested in evaluating ThioBridge™ with a cytolysin payload or the ThioBridge™-cytolysin reagent can be supplied for companies to evaluate in-house.
John Burt, CEO of PolyTherics said “We are delighted to be collaborating with TUBE as the ThioBridge™-cytolysin reagents will provide a new option for companies developing the next generation of antibody drug conjugates.”
Wolfgang Richter, Managing Director of TUBE Pharma, said “TUBE has generated several classes of highly potent tubulysin analogues - the cytolysins - which have shown an excellent anti-cancer effect and safety profile in preclinical studies undertaken by us and our licensees. I am delighted to be working with PolyTherics to generate ThioBridge™-cytolysin reagents for conjugation to antibodies.”
PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.
PolyTherics’ portfolio of services and technologies includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals and through its Cambridge, UK-based subsidiary, Antitope, services for protein immunogenicity assessment and antibody and protein re-engineering technologies are delivered. The group provides its services and technologies to an international client base that includes most of the world’s leading biotechnology and pharmaceutical companies.
PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individuals’ funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.
About TUBE Pharmaceuticals GmbH
TUBE Pharmaceutical is dedicated to the development of powerful anti-cancer drugs derived from natural products. The Company is developing a pipeline of synthetic compounds that can be readily modified to couple them to almost any kind of carrier, including antibodies, peptides and polymers, so that they can be delivered to their site of action. The proprietary tubulysins (cytolysins) and next generation epothilones produced by TUBE will form the basis for the creation of safer and more efficacious products for cancer.
TUBE Pharmaceuticals GmbH is a privately owned Austrian company and obtained financing from aws (Austrian Wirtschaftsservice GmbH) and its shareholders. The Company has laboratories in Vienna, Austria.
For more information, please contact:
John Burt, PolyTherics
Tel.: +44 (0)20 7691 3580
Mark Swallow, Sita Shah or Chris Gardner, Citigate Dewe Rogerson (for PolyTherics)
Tel.: +44 (0) 20 7638 9571
Wolfgang Richter, TUBE Pharmaceuticals GmbH
Tel.: +43 (0)1 740935100
DDI: +44 (0)20 7282 1052
Tel: +44 (0)20 7638 9571
Mob: +44 (0)7903 321 032
Citigate Dewe Rogerson
3 London Wall Buildings
London EC2M 5SY
Posted: October 2013